Measuring Beta-Tubulin Iii, Bcl-2, And Ercc1 Improves Pathological Complete Remission Predictive Accuracy In Breast Cancer
Xiaosong Chen,Jiayi Wu,Hongfen Lu,Ou Huang,Kunwei Shen
DOI: https://doi.org/10.1111/j.1349-7006.2011.02135.x
IF: 5.7
2012-01-01
Cancer Science
Abstract:Weekly PCb (paclitaxel + carboplatin) in neoadjuvant chemotherapy (NCT) for breast cancer has a high pathological complete remission (pCR) rate. The present study was to identify pCR predictive biomarkers and to test whether integrating candidate molecular biomarkers can improve the pCR predictive accuracy. Ninety-one breast cancer patients treated with weekly PCb NCT were retrospectively analyzed. Eleven candidate molecular biomarkers (Tau, beta-tubulin III, PTEN, MAP4, thioredoxin, multidrug resistance-1, Ki67, p53, Bcl-2, BAX, and ERCC1) were detected by immunohistochemistry in pre-NCT core needle biopsy specimens. We analyzed the relationship between these biomarkers and pCR. Univariate analysis showed that estrogen receptor, progesterone receptor, molecular classification (clinicopathological markers), and Tau, beta-tubulin III, p53, Bcl-2, ERCC1 (candidate molecular biomarkers) expression were associated with pCR rate; however, multivariate analysis revealed that only beta-tubulin III, Bcl-2, and ERCC1 were independent pCR predictive factors. Patients with beta-tubulin III negative, Bcl-2 negative, or ERCC1 negative tumors were associated with higher pCR rate, with OR (odds ratios) 6.03 (95% confidence interval [CI], 1.4425.24, P = 0.014), 7.54 (95% CI, 1.5237.40, P = 0.013), and 4.09 (95% CI, 1.1714.30, P = 0.028), respectively. To compare different logistic regression models, built with different combinations of these variables, we found that the model integrating routine clinical and pathological variables, as well as the beta-tubulin III, Bcl-2, ERCC1 molecular biomarkers had the highest pCR predictive power. The area under the ROC curve for this model was 0.900 (95% CI, 0.8310.968), indicating that it deserves further investigation. Trial name: Weekly Paclitaxel Plus Carboplatin in Preoperative Treatment of Breast Cancer. (Cancer Sci 2012; 103: 262268)